Navigation Links
Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

s, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN, INGN 241, and INGN 007 clinical development programs. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com.

Contact

Introgen Therapeutics, Inc., Austin
C. Channing Burke, 512-708-9310, ext. 322
c.burke@introgen.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... ultra rapid acting insulin presented at the American Diabetes ... ORLEANS, June 6 /PRNewswire-FirstCall/ -- ... investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA ... to standard of care therapies in controlling post-meal blood ...
... June 6 Boehringer Ingelheim Pharmaceuticals, Inc. today announced ... the type 2 diabetes therapeutic area. The Company ... clinical development worldwide. New Phase II data results ... inhibitor and the Company,s lead diabetes compound, were presented ...
Cached Medicine Technology:Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 2Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 3Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... only about half as likely as white women to become ... and the racial disparity persists even when donor eggs are ... patients became pregnant after IVF, compared to about 17 percent ... over two years to tease out the impact of race, ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... ER visits and additional imaging services , CHICAGO, ... quickly could cut by half the amount paid for hospital ... Clinical Congress of the American College of Surgeons. According to ... gallstones at the University of North Carolina in 2008, the ...
... onerous, futile medical interventions are ordered for these end-stage ... -- Many people see end-stage dementia as affecting only ... disease,s effects are far-reaching and eventually fatal. , ... not a terminal condition can have negative ...
... ... organization (PPO) plans in Albany, Essex, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, and Washington counties, ... Medicare Choices individual PPO plans now serve Medicare-eligibles in 23 counties, while its group ... ...
... between brain and device , WEDNESDAY, Oct. 14 (HealthDay ... connections between prosthetic hands and the brain, potentially paving ... type, sense hot and cold, and touch others. , ... "would allow people to have a prosthetic that functions ...
... 14 The National Women,s Law Center,s (NWLC) groundbreaking ... Health Insurance Market Fails Women," first released in ... discriminates against women. Now, this ground-breaking research has resulted ... signed by Governor Schwarzenegger over the weekend -- that ...
... Oct. 14 The Guardian Life Insurance Company of America ... leading provider of employee and voluntary benefits for small and ... products and their sales force according to a study conducted ... that Guardian received "very good to excellent" ratings on all ...
Cached Medicine News:Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 2Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 3Health News:Families Need to Know When Dementia Becomes Terminal 2Health News:Families Need to Know When Dementia Becomes Terminal 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 2Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 4Health News:Fine-Tuning Prosthetic Hands to Restore a Sense of Touch 2Health News:National Women's Law Center Challenges Insurance Industry Practices That Treat Being a Woman Like a 'Pre-Existing Condition' 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 3
... identified in 1980 (1) and has only recently ... (2). PYY is produced by the gut and ... is found to decrease appetite. The main form ... is PYY3-36, the N-terminal truncated form of the ...
... Human sex hormone-binding globulin (SHBG) is ... steroids with relatively high specificity and low ... bound to SHBG) and, to a much ... C18 and C19 steroid structures and regulates ...
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
Medicine Products: